Overview

A Clinical Study on the Safety and Efficacy of GP681 Tablets in the Treatment of Uncomplicated Acute Influenza

Status:
Recruiting
Trial end date:
2022-01-25
Target enrollment:
Participant gender:
Summary
Analyse the time of flu symptom relief in adults with uncomplicated acute influenza,to evaluate the antiviral effects of high and low doses of GP681 tablets, and explore the optimal dose for phase III clinical trials.
Phase:
Phase 2
Details
Lead Sponsor:
Jiangxi Qingfeng Pharmaceutical Co. Ltd.